Azacyclic FTY720 Analogues That Limit Nutrient Transporter Expression but Lack S1P Receptor Activity and Negative Chronotropic Effects Offer a Novel and Effective Strategy to Kill Cancer Cells in Vivo
- 14 December 2015
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 11 (2) , 409-414
Abstract
FTY720 sequesters lymphocytes in secondary lymphoid organs through effects on sphingosine-1-phosphate (S1P) receptors. However, at higher doses than are required for immunosuppression, FTY720 also functions as an anticancer agent in multiple animal models. Our published work indicates that the anticancer effects of FTY720 do not depend on actions at S1P receptors but instead stem from FTY720s ability to restrict access to extracellular nutrients by down-regulating nutrient transporter proteins. This result was significant because S1P receptor activation is responsible for FTY720s dose-limiting toxicity, bradycardia, that prevents its use in cancer patients. Here, we describe diastereomeric and enantiomeric 3- and 4-C-aryl 2-hydroxymethyl pyrrolidines that are more active than the previously known analogues. Of importance is that these compounds fail to activate S1P1 or S1P3 receptors in vivo but retain inhibitory effects on nutrient transporter proteins and anticancer activity in solid tumor xenograft models. Our studies reaffirm that the anticancer activity of FTY720 does not depend upon S1P receptor activation and uphold the promise of using S1P receptor-inactive azacyclic FTY720 analogues in human cancer patients.Keywords
Funding Information
- National Cancer Institute (R21 CA178230)
- Congressionally Directed Medical Research Programs (W81XWH-11-1-0535)
- American Cancer Society (RSG-11-111-01-CDD)
- National Institute of General Medical Sciences (R01 GM089919)
- Council on Research Computing and Libraries, University of California, Irvine
- William Lawrence and Blanche Hughes Foundation (BWH-54790)
This publication has 23 references indexed in Scilit:
- Fingolimod: A Review of Its Use in Relapsing-Remitting Multiple SclerosisDrugs, 2014
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosisNature Reviews Drug Discovery, 2010
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous systemBritish Journal of Pharmacology, 2009
- Ceramide starves cells to death by downregulating nutrient transporter proteinsProceedings of the National Academy of Sciences, 2008
- FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome–positive acute lymphocytic leukemiaJournal of Clinical Investigation, 2007
- Constrained azacyclic analogues of the immunomodulatory agent FTY720 as molecular probes for sphingosine 1-phosphate receptorsBioorganic & Medicinal Chemistry Letters, 2007
- Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720Blood, 2006
- Sphingosine 1-Phosphate Analogs as Receptor AntagonistsJournal of Biological Chemistry, 2005
- Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart RateJournal of Biological Chemistry, 2004
- Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor AgonistsScience, 2002